WO2020013616A1 - Composition pharmaceutique orale contenant du taxane présentant une stabilité à l'oxydation améliorée - Google Patents

Composition pharmaceutique orale contenant du taxane présentant une stabilité à l'oxydation améliorée Download PDF

Info

Publication number
WO2020013616A1
WO2020013616A1 PCT/KR2019/008513 KR2019008513W WO2020013616A1 WO 2020013616 A1 WO2020013616 A1 WO 2020013616A1 KR 2019008513 W KR2019008513 W KR 2019008513W WO 2020013616 A1 WO2020013616 A1 WO 2020013616A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
oral pharmaceutical
antioxidant
taxane
paclitaxel
Prior art date
Application number
PCT/KR2019/008513
Other languages
English (en)
Korean (ko)
Inventor
이인현
손민희
정재우
박혜진
김솔
Original Assignee
대화제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 대화제약 주식회사 filed Critical 대화제약 주식회사
Publication of WO2020013616A1 publication Critical patent/WO2020013616A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to oral pharmaceutical compositions containing taxanes. Specifically, the present invention relates to an oral pharmaceutical composition comprising taxane having improved oxidation stability by including an antioxidant.
  • Taxanes are diterpenes produced by the genus Taxus and are widely used as chemotherapeutic agents.
  • Examples of taxanes include paclitaxel (Taxol ® ), docetaxel (Taxotere ® or Docecad), cabazitaxel, larotaxel, ortataxel, tecetaxel and the like.
  • paclitaxel which has been widely prescribed for treating various tumors including ovarian carcinoma, breast cancer, head and neck cancer, non-small cell lung cancer, prostate cancer, and Kaposi's sarcoma, is one of the most effective antitumor agents.
  • Taxanes are known to have very low solubility in water, for example paclitaxel-containing formulation Taxol TM is currently formulated in the form of emulsion preconcentrates and is used diluted prior to injection.
  • Taxol TM is currently formulated in the form of emulsion preconcentrates and is used diluted prior to injection.
  • patient compliance patient compliance
  • stability of the formulation the stability of the formulation, and the safety to the human body due to the use of the injection form is being studied for oral formulations.
  • 10-2004-0009015 uses a medium chain triglyceride such as triacetin, a monoglyceride-based compound such as monoolein, and a surfactant such as Tween.
  • An oral taxane-containing solubilizing composition formulated by the present invention has been disclosed.
  • the composition is an oral taxane-containing solubilizing composition having increased bioavailability through high intestinal mucoadhesion by monoglyceride-based compounds such as monoolein.
  • Korean Patent Application Publication No. 10-2007-0058776 discloses an improved method for preparing the oral taxane-containing solubilizing composition, that is, paclitaxel using a medium chain triglyceride, a monoglyceride compound, and a surfactant. It has been disclosed a preparation method comprising dissolving together.
  • composition patent of Korean Patent Application Laid-Open No. 10-2014-0150173 relates to a pharmaceutical composition for oral administration containing taxane, the composition comprising medium chain glyceride, oleyl glycerol complex, and lipids of surfactant as excipients.
  • Oral anticancer agents have been disclosed.
  • oxidation of the lipids may occur depending on the storage conditions, and may be expected to affect the stability of the preparation.
  • the present inventors have completed the present invention by studying the applicable antioxidant to ensure the oxidation stability of the formulation.
  • the present invention provides an oral pharmaceutical composition comprising taxane with improved oxidative stability.
  • the present invention provides a stabilized pharmaceutical composition further comprising an antioxidant to improve oxidation stability in a composition comprising taxane, medium chain triglycerides, oleoyl glycerol complex, and a surfactant.
  • the present invention comprises a taxane and an antioxidant, wherein the antioxidant is at least one selected from the group consisting of dibutyl hydroxy toluene, butylhydroxyanisole, propyl gallate and tocopherol It provides a pharmaceutical composition.
  • the present invention provides oral pharmaceutical compositions comprising taxanes, antioxidants, medium chain triglycerides, oleyl glycerol complexes and surfactants.
  • step (ii) removing the organic solvent from the solution obtained in step (i) to obtain a mixture
  • step (iii) adding an oleyl glycerol complex and a surfactant to the mixture obtained in step (ii);
  • It provides a method for producing an oral pharmaceutical composition comprising a.
  • the oral pharmaceutical composition of the present invention not only secures oxidative stability by including an antioxidant, but can also improve stability of the formulation and prevents changes in the active ingredient and formulation during storage and distribution.
  • Example 1 shows the solution properties of Example (A), Comparative Example 1 (B) and Comparative Example 5 (C).
  • Figure 2 shows the oxidation degree (%) according to the content of the antioxidant dibutyl hydroxy toluene (BHT).
  • Figure 3 shows the oxidation degree (%) according to the content of the antioxidant butylhydroxyanisole (BHA).
  • Figure 4 shows the oxidation degree (%) according to the content of the antioxidant propyl gallate (propyl gallate).
  • Figure 5 shows the oxidation degree (%) according to the content of the antioxidant tocopherol (tocopherol).
  • Figure 6 shows the oxidation degree (%) according to the content of the antioxidant ascorbic acid.
  • Figure 7 shows the oxidation degree (%) at the highest content of the daily intake allowance of each antioxidant.
  • Figure 8 shows the browning phenomenon with or without the antioxidant.
  • the present invention provides oral pharmaceutical compositions comprising taxanes and antioxidants.
  • the taxane may be paclitaxel, docetaxel, 7-epipaclitaxel, t-acetylpaclitaxel, 10-desacetylpaclitaxel, 10-desacetylpaclitaxel, or 10-desac. 10-desacetyl-7-epipaclitaxel, 7-xylosylpaclitaxel, 10-desacetyl-7-glutarylpaclitaxel, 7 At least one selected from the group consisting of -N, N-dimethylglycylpaclitaxel and 7-L-alanylpaclitaxel, preferably paclitaxel.
  • the present invention is not limited thereto.
  • the antioxidant may be at least one selected from the group consisting of dibutyl hydroxy toluene (BHT), butyl hydroxyanisole (BHA), propyl gallate and tocopherol.
  • the antioxidant may include 0.001 to 1.0% by weight, preferably 0.01 to 0.2% by weight based on the total weight of the composition.
  • oral pharmaceutical compositions of the present invention may further comprise medium chain triglycerides, oleyl glycerol complexes and surfactants.
  • the medium chain triglycerides refer to a substance in which three molecules of saturated or unsaturated C 2 -C 20 fatty acids and one molecule of glycerol are connected by an ester bond.
  • the medium chain triglyceride is triacetin, tripropionin, tributyrin, trivalerin, tricaproin, tricaproin, tricapryline ( tricaprylin) [e.g., cap-Tex TM 8000 (Captex TM 8000), etc.], tri-capric (tricaprin), tri cyclohepta elderly (triheptanoin), teurino nano (trinonanoin), tri undead Kano of (triundecanoin), tri La Trilaurin, tritridecanoin, trimyristin, tripentadecanoin, tripalmitin, glyceryl triheptadecanoate and triolein triolein) may be one or more selected from the group consisting of, preferably tricap
  • the medium chain triglycerides may comprise 1 to 40% by weight based on the total weight.
  • the oleoyl glycerol complex refers to a complex obtained by partial glycerolysis of vegetable oil mainly containing triglycerol of oleic acid or by esterification of glycerol and oleic acid. . Partial glycerol degradation and / or esterification results in varying amounts of monooleyl glycerol, dioleyl glycerol, and trioleyl glycerol.
  • oleyl glycerol complexes may be used, such as peceol (PECEOL TM , Gattefosse) or capmal (CAPMUL TM , Abitec), and the like, but may be preferably peseol, but is not limited thereto.
  • the oleyl glycerol complex may comprise 1 to 80% by weight based on the total weight.
  • the surfactant is polyoxyethylene-polyoxypropylene copolymers [e.g., poloxamer TM (Poloxamer TM)], sorbitan esters, for example, Span TM (Span TM)], polyoxyethylene sorbitan EXAMPLES for example, tween TM (tween TM)] and polyoxyethylene ethers [for example, Breeze TM (Brij TM)] with and be at least one selected from the group consisting of, preferably polyoxyethylene be sorbitan tanil However, this It is not limited.
  • the surfactant may include 1 to 70% by weight based on the total weight.
  • step (ii) removing the organic solvent from the solution obtained in step (i) to obtain a mixture
  • step (iii) adding an oleyl glycerol complex and a surfactant to the mixture obtained in step (ii);
  • It provides a method for producing an oral pharmaceutical composition comprising a.
  • the organic solvent may be at least one selected from the group consisting of halogenated alkyl compounds, alcohols and ketones.
  • the halogenated alkyl compound may be a halogenated C 1 to C 5 alkyl compound, preferably methylene chloride or chloroform, more preferably methylene chloride.
  • Paclitaxel, antioxidants and medium chain triglycerides were dissolved in methylene chloride and concentrated under reduced pressure at 40 ° C. to remove methylene chloride.
  • the oral taxane formulation was prepared by stirring at 40 ° C.
  • the antioxidant content of each formulation was calculated based on the Acceptable Daily Intake (mg / kgbw / day).
  • Taxane formulations of Examples 1 to 3 were prepared according to the antioxidant components and contents of Table 1 below. Taxane formulations prepared as shown in FIG. 1 (A) showed clear solution properties.
  • Example 1 Example 2
  • Example 3 Taxane Paclitaxel 1.02 1.02 1.02
  • Antioxidant Dibutyl hydroxy gallate (BHT) 0.01 - - - 0.02 - - - 0.03
  • Taxane formulations of Examples 4 to 6 were prepared according to the antioxidant components and contents of Table 2 below. Taxane formulations prepared as shown in FIG. 1 (A) showed clear solution properties.
  • Example 4 Taxane Paclitaxel 1.02 1.02 1.02 Antioxidant Butylhydroxyanisole (BHA) 0.01 - - - 0.02 - - - 0.05 Excipient Medium Chain Triglycerides 27.00 27.00 26.99 Oleyl Glycerol Complex 18.42 18.42 18.41 Surfactants 53.55 53.54 53.53 Sum(%) 100.00
  • Taxane formulations of Examples 7 to 9 were prepared according to the antioxidant components and contents of Table 3 below. Taxane formulations prepared as shown in FIG. 1 (A) showed clear solution properties.
  • Example 7 Example 8
  • Example 9 Taxane Paclitaxel 1.02 1.02 1.02 Antioxidant Profile gallate 0.04 - - - 0.07 - - - 0.14
  • Taxane formulations of Examples 10 to 12 were prepared according to the antioxidant components and contents of Table 4 below. Taxane formulations prepared as shown in FIG. 1 (A) showed clear solution properties.
  • Example 10 Example 11
  • Example 12 Taxane Paclitaxel 1.02 1.02 1.02
  • Paclitaxel and medium chain triglycerides were dissolved in methylene chloride and then concentrated under reduced pressure at 40 ° C. to remove methylene chloride.
  • Comparative Example 1 containing no antioxidant was prepared according to the ingredients and contents of Table 5 below. As shown in Figure 1 (B), the prepared taxane formulation showed a clear solution properties.
  • Paclitaxel, antioxidants and medium chain triglycerides were dissolved in methylene chloride and concentrated under reduced pressure at 40 ° C. to remove methylene chloride.
  • Examples 1 to 3 using dibutyl hydroxy toluene (BHT) as the antioxidant showed an oxidation degree of less than 20%. Accordingly, it was found from Examples 1 to 3 that all exhibited similar antioxidant effects of 80% or more regardless of the BHT content.
  • BHT dibutyl hydroxy toluene
  • Examples 4 to 6 using butylhydroxyanisole (BHA) as an antioxidant showed an oxidation degree of about 30%. Thus, it was found from Examples 4 to 6 that all exhibited similar antioxidant effects of about 70% regardless of the BHA content.
  • BHA butylhydroxyanisole
  • Examples 7 to 9 using propyl gallate as an antioxidant showed an oxidation degree of less than about 10%. Therefore, it can be seen from Examples 7 to 9 that as the content increases, the degree of oxidation decreases and the antioxidant effect increases.
  • Examples 10 to 12 using the tocopherol (tocopherol) as an antioxidant showed an oxidation degree of about 40 to 70%, the oxidation degree is greatly reduced as the content is increased, the antioxidant effect is increased I could see that.
  • the oxidation degree at the highest content of the daily intake allowance of each antioxidant is shown in FIG. 7, and as shown in FIG. 7, the highest antioxidant effect was shown at 0.14% by weight of propyl gallate, and BHT, BHA and Both tocopherols showed excellent antioxidant effects.
  • Example 1 and Comparative Example 1 were stored under severe conditions (70 ° C.), the browning of the formulations was confirmed by observing the properties of each sample at 0, 3, 6 and 12 months. 8 is shown.
  • Example (A) containing an antioxidant it was confirmed that browning did not occur until 12 months and the appearance was maintained. Therefore, the browning prevention effect of the formulation containing antioxidant BHT was confirmed.
  • an antioxidant in the formulation containing taxane may have an antioxidant and browning effect, among the antioxidants, dibutyl hydroxy toluene (BHT), butyl hydroxyanisole (BHA), propyl gallate (propyl gallate) and tocopherol (tocopherol) show an excellent effect, but ascorbic acid does not show an excellent antioxidant effect, it can be seen that high content ascorbic acid is not well dissolved in the formulation.
  • BHT dibutyl hydroxy toluene
  • BHA butyl hydroxyanisole
  • propyl gallate propyl gallate
  • tocopherol tocopherol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique orale contenant du taxane. Spécifiquement, la présente invention concerne une composition pharmaceutique orale comprenant du taxane présentant une stabilité à l'oxydation améliorée du fait qu'elle renferme un antioxydant.
PCT/KR2019/008513 2018-07-11 2019-07-10 Composition pharmaceutique orale contenant du taxane présentant une stabilité à l'oxydation améliorée WO2020013616A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0080350 2018-07-11
KR1020180080350A KR102093100B1 (ko) 2018-07-11 2018-07-11 산화 안정성이 향상된 탁산을 포함하는 경구용 약학 조성물

Publications (1)

Publication Number Publication Date
WO2020013616A1 true WO2020013616A1 (fr) 2020-01-16

Family

ID=69142051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/008513 WO2020013616A1 (fr) 2018-07-11 2019-07-10 Composition pharmaceutique orale contenant du taxane présentant une stabilité à l'oxydation améliorée

Country Status (2)

Country Link
KR (1) KR102093100B1 (fr)
WO (1) WO2020013616A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102447753B1 (ko) * 2022-05-23 2022-09-27 곽민석 기능 보완과 도장이 편리한 기능성 새시의 제조방법

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045357A1 (fr) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Formules pharmaceutiques orales contenant du paclitaxel et des derives, et methodes d'administration de celles-ci
KR20040009015A (ko) * 2002-07-20 2004-01-31 한국과학기술연구원 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
KR20040009016A (ko) * 2002-07-20 2004-01-31 한국과학기술연구원 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
WO2012028310A2 (fr) * 2010-08-31 2012-03-08 Avidal Vascular Gmbh Compositions pharmaceutiques contenant un taxane
KR101542364B1 (ko) * 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
KR101612255B1 (ko) * 2015-07-30 2016-04-20 대화제약 주식회사 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
KR101612257B1 (ko) * 2015-07-30 2016-04-20 대화제약 주식회사 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
KR20170020479A (ko) * 2014-06-19 2017-02-22 솔루랄 파마 에이피에스 친유성 화합물의 고형 경구 투여 형태

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045357A1 (fr) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Formules pharmaceutiques orales contenant du paclitaxel et des derives, et methodes d'administration de celles-ci
KR20040009015A (ko) * 2002-07-20 2004-01-31 한국과학기술연구원 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
KR20040009016A (ko) * 2002-07-20 2004-01-31 한국과학기술연구원 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
WO2012028310A2 (fr) * 2010-08-31 2012-03-08 Avidal Vascular Gmbh Compositions pharmaceutiques contenant un taxane
KR20170020479A (ko) * 2014-06-19 2017-02-22 솔루랄 파마 에이피에스 친유성 화합물의 고형 경구 투여 형태
KR101542364B1 (ko) * 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
KR101612255B1 (ko) * 2015-07-30 2016-04-20 대화제약 주식회사 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
KR101612257B1 (ko) * 2015-07-30 2016-04-20 대화제약 주식회사 고농도의 탁산을 포함하는 경구 투여용 약학 조성물

Also Published As

Publication number Publication date
KR102093100B1 (ko) 2020-03-26
KR20200006682A (ko) 2020-01-21

Similar Documents

Publication Publication Date Title
EP4289482A9 (fr) Forme galénique d'édaravone
EP2616053B1 (fr) Compositions pharmaceutiques de curcumine
US11116744B2 (en) Pharmaceutical composition for oral administration comprising taxane
WO2017196148A1 (fr) Formulation composite de dutastéride et de tadalafil comprenant un dérivé d'ester d'acide gras de glycérol ou un dérivé d'ester d'acide gras de propylène glycol et formulation de capsule orale comprenant celle-ci
ITRM940621A1 (it) "composizione farmaceutica stabilizzata, relativo solvente e procedimento di preparazione"
KR20060110872A (ko) 토코페롤 변성 치료제 약물 화합물
WO2020013616A1 (fr) Composition pharmaceutique orale contenant du taxane présentant une stabilité à l'oxydation améliorée
US6316497B1 (en) Self-emulsifying systems containing anticancer medicament
KR101612255B1 (ko) 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
WO2017018634A1 (fr) Composition pharmaceutique pour l'administration par voie orale comprenant un taxane à haute concentration
KR20060052834A (ko) 탁소이드의 경구 투여용 자가-유화 및 자가-마이크로유화제형
WO2020009486A1 (fr) Procédé d'amélioration de la stabilité d'un médicament contenant une composition pharmaceutique contenant un taxane
WO2024076056A1 (fr) Composition pharmaceutique orale contenant un taxane et son procédé de préparation
KR20070058776A (ko) 파클리탁셀 조성물의 제조 방법
KR101612259B1 (ko) 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
WO2017018635A1 (fr) Composition pharmaceutique pour administration orale comprenant du taxane à haute concentration
KR101612260B1 (ko) 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
KR20200035383A (ko) 탁산-함유 약학 조성물을 함유하는 의약품의 안정성 개선방법
RU2340616C2 (ru) Токоферол-модифицированные терапевтические лекарственные соединения
WO2018062831A1 (fr) Formulation composite de capsule orale contenant du dutastéride et du tadalafil
KR20080034989A (ko) 토포이소머라제 ｉ 억제제７-ｔｅｒｔ-부톡시이미노메틸캄토테신의 마이크로입자조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19833893

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19833893

Country of ref document: EP

Kind code of ref document: A1